Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EV1L
|
|||
| Former ID |
DIB016178
|
|||
| Drug Name |
Elsiglutide
|
|||
| Synonyms |
Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma
Click to Show/Hide
|
|||
| Indication | Diarrhea [ICD-11: ME05.1; ICD-9: 787.91] | Phase 2 | [1] | |
| Company |
Zealand Pharma A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 2 receptor (GLP2R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01543451) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea. U.S. National Institutes of Health. | |||
| REF 2 | Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.